Jamieson Wellness Inc. Declares Third Quarter 2020 Dividend

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the board of directors of the Company has declared a cash dividend for the third quarter of 2020 of $0.125 per common share, or approximately $5.0 million in the aggregate. The dividend will be paid on December 15, 2020 to all common shareholders of record at the close of business on December 1, 2020. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions by Lorna Vanderhaeghe, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Jamieson Wellness
Ruth Winker
416-960-0052
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
 Thian Chew, CEO of Invion

New Deal Could Spark Invion’s Entry into Pet Cancer Market, CEO Says

Invion’s (ASX:IVX,OTC Pink:IVIXF) Photosoft cancer treatment technology has entered an important milestone, thanks to a new collaboration deal with Taiwanese firm Protect Animal Health, to undertake studies to treat cancer in pets.“The significance of this recent collaboration is (that) now... Keep Reading...
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...

Latest Press Releases

Related News